Advertisement

Parkinson’s Disease: Etiologic Considerations

  • Peter A. LeWitt
Part of the Current Clinical Practice book series (CCP)

Abstract

Parkinson’ s disease (PD) is associated with distinctive and highly localized pathologic changes in the brain. Degeneration of substantia nigra pars compacta neurons within the midbrain is pronounced in patients with PD. These dopaminergic neurons project to the striatum, and loss of striatal dopamine is responsible for most of the motor deficits of PD.

Keywords

Substantia Nigra Multiple System Atrophy Lewy Body Essential Tremor Striatal Dopamine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected Reading

  1. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995; 38: 357–366.PubMedCrossRefGoogle Scholar
  2. Ben-Shlomo Y. How far are we in understanding the cause of Parkinson’s disease? J Neurol Neurosurg Psychiatry 1996; 61: 4–16.PubMedCrossRefGoogle Scholar
  3. Caine DB. Is idiopathic parkinsonism the consequence of an event or a process? Neurology 1994; 44: 5–10.CrossRefGoogle Scholar
  4. Golbe LI. The epidemiology of Parkinson’s disease, in Parkinson’s Disease: The Treatment Options ( LeWitt PA, Oertel WH eds), Martin Dunitz Publishers, London, 1999, pp. 63–77.Google Scholar
  5. Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC. Risk factors for Parkinson’ s disease. Neurology 1993; 43: 1693–1697.PubMedCrossRefGoogle Scholar
  6. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson’s disease. Mov Disord 1998; 13 Suppl 1: 24–34.PubMedGoogle Scholar
  7. Kopin IJ, Markey SP. MPTP toxicity: implications for research in Parkinson’s disease. Ann Rev Neurosci 1988; 11: 81–96.PubMedCrossRefGoogle Scholar
  8. Le WD, Rowe DB, Jankovic J, Xie W, Appel SH. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol 1999; 56: 194–200.PubMedCrossRefGoogle Scholar
  9. McGeer EG, McGeer PL. Neurodegeneration and the immune system, in Neurodegenerative Diseases (Caine DB ed), W. B. Saunders Company, Philadelphia, 1994, pp. 277–300.Google Scholar
  10. Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993; 52: 183–191.PubMedCrossRefGoogle Scholar
  11. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997; 276: 2045–2047.PubMedCrossRefGoogle Scholar
  12. Quinn N, Critchley P, Marsden CD. Young onset Parkinson’s disease. Mov Disord 1987; 2: 73–91.PubMedCrossRefGoogle Scholar
  13. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW. Parkinson disease in twins: an etiologic study. JAMA 1999; 281: 341–346.PubMedCrossRefGoogle Scholar
  14. Youdim MB, Ben-Shachar D, Riederer P. The possible role of iron in the etiopathology of Parkinson’s disease. Mov Disord 1993; 8: 1–12.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Peter A. LeWitt

There are no affiliations available

Personalised recommendations